Each year, thousands of doctors, scientists, students, industry and patient advocacy groups like National Eczema Association, gather to hear the latest research and standards of medical care in dermatology at the American Academy of Dermatology (AAD) Annual Meeting.
Atopic dermatitis is a hot field of study. Here’s some highlights from this year’s AAD meeting.
Biologic tralokinumab shows positive results in clinical studies for the treatment of atopic dermatitis
Tralokinumab, an investigational biologic drug, showed positive results in Phase 2b clinical trials in adults with moderate to severe atopic dermatitis. This investigational drug targets the cytokine interleukin 13 (IL-13). When functioning correctly, IL-13 helps regulate the immune system and inflammation in the body.
LEO Pharma is researching tralokinumab. The company expects to move into the next phase of clinical trial study in the first half of 2017.
New 52-week data show biologic dupilumab significantly improves atopic dermatitis symptoms as compared to steroids alone
New data from clinical trials shows that dupilumab, an investigational biologic treatment, significantly reduces the severity of symptoms of atopic dermatitis in adults. Specifically, patients in the trials experienced improved quality of life, reduced itch and notably higher rates of clear or almost clear skin as compared to patients who were using just steroids. The data was collected from more than 700 patients at week 16 and week 52 of their treatment with dupilumab alone, dupilumab and a steroid in combination or a steroid alone.
Dupilumab targets IL-4 and IL-13 to regulate the immune system response in atopic dermatitis. The Food and Drug Administration is expected to make a decision on approval of dupilumab in March 2017.
Topical tofacitinib shows promise for eczema and other dermatological diseases
Tofacitinib, a Janus kinase (JAK) inhibitor approved in oral form for rheumatoid arthritis may have promise as a potential treatment for alopecia, vitiligo and eczema.
JAK inhibitors work by interrupting cytokines from “signaling” one another through the Janus kinase enzyme family. This signaling contributes to inflammation, resulting in symptoms common to eczema.
A preliminary study of 69 patients with mild to moderate atopic dermatitis, showed that topical application of tofacitinib reduced symptoms of itch in as soon as 48 hours. Participants in the study reported significant reductions in itch and improved sleep.